Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
Articolo
Data di Pubblicazione:
2018
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
lenalidomide; mantle cell lymphoma; non-Hodgkin lymphoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Recurrence; Retreatment; Thalidomide; Treatment Outcome; Hematology
Elenco autori:
Arcaini, Luca; Lamy, Thierry; Walewski, Jan; Belada, David; Mayer, Jiri; Radford, John; Jurczak, Wojciech; Morschhauser, Franck; Alexeeva, Julia; Rule, Simon; Cabeçadas, José; Campo, Elias; Pileri, Stefano A.; Biyukov, Tsvetan; Patturajan, Meera; Casadebaig Bravo, Marie-Laure; Trnĕný, Marek
Link alla scheda completa:
Pubblicato in: